1. Scrip
  2. >>Therapy Areas
  3. >>Anticancer

BMS' Opdivo Heading Towards Indian Debut?

 
• By Anju Ghangurde

Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo (nivolumab) appears to be on course to a potential Indian debut, after a key local expert panel recommended the product for marketing.

Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo (nivolumab) appears to be on course to a potential Indian debut, after a key local expert panel recommended the product for marketing.

A subject expert committee (SEC), which advises the Indian regulator on trial-related permissions as part of a layered approval process,...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anticancer

More from Therapy Areas

Spyre Takes Aim At Roche And J&J In Inflammatory Diseases

 
• By Andrew McConaghie

The US firm was already looking to compete in ulcerative colitis, but now expands its ambitions by moving into rheumatoid arthritis as well.

Draig Is All Fired Up To Transform Neuropsychiatric Field

 
• By Kevin Grogan

Wales-based group launches with $140m series A.

Immuneering Could Partner Atebimetinib Or Go It Alone After Phase IIa Success

 
• By Alaric DeArment

CEO Ben Zeskind said all options are on the table after atebimetinib showed impressive results in pancreatic cancer.